HN3Q

Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. The comapny engages in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome. It has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay.